We are monitoring the impact of COVID-19 on APAC Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 1122
Share on
Share on

Asia Pacific Monoclonal Antibodies Market Research Report – Segmented By Source, Indication, End-User, Application, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2019 - 2024

Pulished: August, 2019
ID: 1122
Pages: 137

APAC Monoclonal Antibodies Market Size & Growth (2019 - 2024)

According to our report, the size of the Monoclonal Antibodies Market in the Asia Pacific is estimated to be USD 5.94 Billion in 2019 and expected to grow at a Compound Annual Growth Rate of 4.52%, to reach USD 10.99 Billion by 2024.

mAb`s are antibodies that are made by identical immune cells that are all clones of a unique parent cell, in distinction to polyclonal antibodies, which are made by numerous different immune cells. Monoclonal Antibody market in the Asia-Pacific region is gaining momentum due to increasing awareness among patients and physicians about the application of mAb`s in various diseases.

Asia-Pacific Monoclonal Antibodies market is driven by factors such as patent expiries of key biological drugs, aging population, increasing disposable income, and supporting the legislation. The development of new molecules is also expected to play a key role in the future of the market. Rising government initiatives supporting the use of mAbs for research and treatment purposes along with an upsurge in R&D activities for the development of cost-effective therapeutic mAbs are also driving the market for Monoclonal Antibodies market.

However, the amount of money and time required for the identification and development of potential molecules is huge and is a major factor restraining the market growth.

This research report has been segmented & sub-segmented into the following categories:

  • By Source: Murine, Chimeric, Humanized and Human
  • By Indication: Cancer (Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer and Others), Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, CNS Disorders and Others (Inflammatory, Microbial Diseases, & Other)
  • By End-User: Hospitals/Clinics, Research Institute and Diagnostic Laboratories
  • By Application: Medical, Experimental, Western Blot (ELISA, Radioimmune Assays, Immunofluorescence and Others)
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

On the basis of source, the Human mAb`s is the largest segment by source accounting for a share of around XX%.

On the basis of end-user, the Hospitals segment is the largest end-user segment accounting for a share of approximately XX%.

Regionally, Asia-Pacific is the fastest-growing region for the Monoclonal antibodies market owing to the huge population and increasing disposable income of people. Within Asia-Pacific, China is the largest market while India is estimated to be the fastest-growing.

Leading companies in the APAC Monoclonal Antibodies Market profiled in this report are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. and Biogen Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Innovent Biologics (China)                   

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Shanghai Junshi Bioscience Co.,Ltd. (China)                  

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  2. Asia-Pacific Chimeric Market By Region, From 2019 - 2024 ( USD Million )
  3. Asia-Pacific Humanized Market By Region, From 2019 - 2024 ( USD Million )
  4. Asia-Pacific Human Market By Region, From 2019 - 2024 ( USD Million )
  5. Asia-Pacific Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  6. Asia-Pacific Autoimmune Diseases Market By Region, From 2019 - 2024 ( USD Million )
  7. Asia-Pacific Infectious Diseases Market By Region, From 2019 - 2024 ( USD Million )
  8. Asia-Pacific Cardiovascular Diseases Market By Region, From 2019 - 2024 ( USD Million )
  9. Asia-Pacific CNS Disorders Market By Region, From 2019 - 2024 ( USD Million )
  10. Asia-Pacific Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2019 - 2024 ( USD Million )
  11. Asia-Pacific Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  12. Asia-Pacific Research Institute Market By Region, From 2019 - 2024 ( USD Million )
  13. Asia-Pacific Diagnostic Laboratories Market By Region, From 2019 - 2024 ( USD Million )
  14. Asia-Pacific Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  15. Asia-Pacific Experimental Market By Region, From 2019 - 2024 ( USD Million )
  16. Japan Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  17. Japan Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  18. Japan Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  19. Japan Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  20. China Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  21. China Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  22. China Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  23. China Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  24. India Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  25. India Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  26. India Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  27. India Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  28. South Korea Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  29. South Korea Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  30. South Korea Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  31. South Korea Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  32. Australia Monoclonal Antibodies Market By Murine, From 2019 - 2024 ( USD Million )
  33. Australia Monoclonal Antibodies Market By Cancer, From 2019 - 2024 ( USD Million )
  34. Australia Monoclonal Antibodies Market By Hospitals/Clinics, From 2019 - 2024 ( USD Million )
  35. Australia Monoclonal Antibodies Market By Medical, From 2019 - 2024 ( USD Million )
  36. Asia-Pacific Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  37. Asia-Pacific Breast Cancer Market By Region, From 2019 - 2024 ( USD Million )
  38. Asia-Pacific Colorectal Cancer Market By Region, From 2019 - 2024 ( USD Million )
  39. Asia-Pacific Lung Cancer Market By Region, From 2019 - 2024 ( USD Million )
  40. Asia-Pacific Pancreatic Cancer Market By Region, From 2019 - 2024 ( USD Million )
  41. Asia-Pacific Others Market By Region, From 2019 - 2024 ( USD Million )
  42. Japan Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  43. China Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  44. India Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  45. Souh Korea Monoclonal Antibodies Market By Blood Cancer, From 2019 - 2024 ( USD Million )
  46. Asia-Pacific Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  47. Asia-Pacific ELISA Market By Region, From 2019 - 2024 ( USD Million )
  48. Asia-Pacific Radioimmune Assays Market By Region, From 2019 - 2024 ( USD Million )
  49. Asia-Pacific Immunofluorescence Market By Region, From 2019 - 2024 ( USD Million )
  50. Asia-Pacific Others Market By Region, From 2019 - 2024 ( USD Million )
  51. Japan Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  52. China Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  53. India Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )
  54. Souh Korea Monoclonal Antibodies Market By Western Blot, From 2019 - 2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample